Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval for Additional Doses to Treat Type 2 Diabetes
Shots:
- The approval is based on P-III AWARD-11 study assessing Trulicity (3.0mg & 4.5mg, qw) vs Trulicity (1.5 mg) in 1,842 patients with T2D
- The P-III study demonstrated that additional doses led to further benefits in A1C (-17% & -19% vs -1.5%) and bodyweight reduction (-8.8 & -10.4 vs -6.8 pounds) @36wks. in people with inadequately controlled T2D on concomitant metformin therapy respectively
- The P-III study results are under EMA’s review for approval, expected this year. The additional doses of Trulicity will be available in US’ pharmacies later this month
Click here to read full press release/ article | Ref: PRNewswire | Image: S&P Global